Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.
Actively Recruiting
Researchers are investigating the long-term safety and effectiveness of a combined drug treatment using xanomeline tartratetrospium chloride in an immediate release capsule KarXT and xanomeline enteric capsules KarX-EC for people with agitation linked to Alzheimers Disease. This study is an open-label extension of earlier studies CN012-0023 and CN012-0024. It aims to understand how well these treatments work over time and monitor any side effects. Participants who completed the previous studies will receive specified doses of KarXT and KarX-EC according to a set schedule. This phase 3 study does not include a comparison group and all participants receive the combined treatment. The treatment period lasts approximately 30 weeks, during which the effects and safety of these medications will be observed. During the study, participants will be closely monitored for any adverse events, changes in cognitive function, movement disorders, vital signs, and other health measures. Assessments include scales like the Mini-Mental State Examination MMSE, Abnormal Involuntary Movement Scale AIMS, and others related to agitation and side effects. Safety checks such as lab tests, ECGs, and questionnaires will be regularly conducted. The total study duration for participants is about 30 weeks, with follow-up to evaluate overall treatment tolerability and impact.
Actively Recruiting
This research aims to study children and adolescents aged 2 to 17 years who have fibrosing interstitial lung disease ILD. The trial evaluates how the drug nerandomilast is tolerated, processed by the body, and whether it helps young patients with ILD. Nerandomilast has been approved in some countries for adults with a similar lung condition called idiopathic pulmonary fibrosis. The study is designed to better understand the effects and safety of nerandomilast in this younger population. Participants aged 6 to 17 years are randomly assigned to one of two groups for the first part of the study one group receives nerandomilast, and the other receives a placebo that looks like the medicine but contains no active drug. They take tablets twice daily for 6 months. After this, all participants in this age group receive nerandomilast for at least 2 years in the second part of the study. Younger participants aged 2 to 5 years start nerandomilast treatment immediately and take the tablets twice daily for at least two and a half years. Over the course of the study, which lasts between two and a half to five years depending on when participants join, individuals may have about 18 to 30 visits to the study site. During these visits, doctors collect blood samples to monitor health and how the body handles the medicine. Lung function, growth, and quality of life are also regularly assessed. For participants aged 6 to 17 years, results from the nerandomilast group are compared to those receiving placebo to evaluate treatment effects.
Actively Recruiting
Phase 3 Study of Rimegepant for Intermittent Prevention of Menstrual Migraine in Women Aged 18 to 45
Researchers are evaluating the use of rimegepant for intermittent prevention of menstrual migraine in women aged 18 to 45 who experience migraine attacks related to their menstrual cycle. This Phase 3, double-blind, randomized study compares rimegepant with placebo to assess its efficacy and safety during the peri-menstrual period. The study focuses on migraine frequency and severity in women with a history of menstrual migraine and regular menstrual cycles. Participants receive either rimegepant 75 mg orally disintegrating tablets for 7 days during each peri-menstrual period or a matching placebo, along with standard care for acute migraine treatment as needed. The study treatment cycles are repeated over 5 menstrual cycles in the double-blind treatment phase. The study also includes an acute treatment dosing option with rimegepant as needed. During the study, participants will be monitored for changes in the number of migraine and headache days, use of migraine medications, and functional disability related to migraine. Cognitive function is also assessed. Researchers will conduct evaluations over 5 months, covering 5 menstrual cycles, and measure outcomes related to migraine frequency and severity during the peri-menstrual period. Safety and tolerability will be closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating the effectiveness of riliprubart compared to the usual treatment of intravenous immunoglobulin IVIg in adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP who are currently receiving maintenance IVIg therapy. This Phase 3 randomized study aims to understand how well riliprubart works in this group over a study duration of up to 109 weeks, including screening, treatment, and follow-up periods. Participants are randomly assigned to one of two groups one group receives riliprubart along with a placebo IVIg infusion for 24 weeks, followed by an open-label extension phase with riliprubart for another 24 weeks the other group continues IVIg treatment with a placebo riliprubart for 24 weeks, then also enters the open-label riliprubart extension. Treatments are given as intravenous or subcutaneous infusions, and dosing follows established maintenance regimens. During the study, participants will have regular assessments to monitor their response to treatment. These include measuring disability and fatigue scales, grip strength, and relapse rates from baseline through various time points up to week 109. Safety is monitored by tracking treatment-emergent adverse events and antibody development. Participants are followed closely through scheduled visits to evaluate changes in their condition and overall health status throughout the study.
Actively Recruiting
Researchers are studying nerandomilast as a potential treatment for adults with systemic sclerosis SSc, a condition that causes skin thickening and affects internal organs. This phase 3 trial aims to evaluate whether nerandomilast improves symptoms and slows disease progression in people with limited or diffuse cutaneous SSc who have had disease onset within 7 years of their first non-Raynauds symptom. The study is sponsored by Boehringer Ingelheim and compares nerandomilast to a placebo in a double-blind, randomized design. Participants are randomly assigned to one of two groups one group takes nerandomilast tablets and the other takes placebo tablets. Both types of tablets are film-coated and look the same. Participants take these tablets twice daily. The study lasts from 1 to about 4 years, during which participants attend regular visits and receive phone calls from study staff. The trial includes adults with active disease who may be untreated or on stable immunosuppressive treatments. During the study, participants undergo repeated assessments including blood tests and evaluations of skin thickening, lung function, and overall health. Doctors also monitor internal organs and check for any side effects or safety concerns related to the treatment. The main outcome measured is the time until disease progression or death over up to 4 years. Other outcomes include changes in skin score, lung function, and quality of life. Safety and tolerability are closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are investigating the long-term safety of eptinezumab in children and adolescents aged 6 to 17 who have chronic or episodic migraine. This extension study involves participants who completed previous related studies and aims to continue monitoring their response to the treatment over an extended period. The study is phase 3 and evaluates the effects of eptinezumab to better understand its safety profile in this younger population. Participants will receive eptinezumab through intravenous infusions in one of two dose groups 100 mg or 300 mg, both adjusted by weight. Those who received these doses in prior studies will continue the same dose, while those previously on placebo will be randomly assigned to one of the two dose groups with equal chance. Each participant will receive three infusions at weeks 0, 12, and 24 during the open-label extension. Throughout the study, participants will undergo various assessments including tracking of adverse events, blood tests measuring eptinezumab levels and antibodies, and evaluations of migraine disability using the Pediatric Migraine Disability Assessment Questionnaire at specified weeks. The study extends up to week 44, with safety and efficacy monitoring continuing throughout, ensuring comprehensive data collection on the long-term effects of eptinezumab in this age group.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of nipocalimab compared to a placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP who initially respond to nipocalimab treatment. The study focuses on delaying relapse in this population and involves multiple phases and stages to assess the treatments impact. This trial is sponsored by Janssen Research & Development, LLC and includes adults diagnosed with CIDP according to specific criteria. Participants first enter Stage A, where they receive an initial loading dose of nipocalimab by intravenous infusion on Day 1, followed by doses every two weeks from Week 2 to Week 12. Those who show clinical improvement proceed to Stage B, a double-blind phase where they are randomly assigned to receive either nipocalimab or placebo infusions every two weeks for up to 52 weeks. Following Stage B, participants may join an open-label extension phase to continue receiving nipocalimab every two weeks until two years after the drugs marketing authorization in their country or until it becomes commercially available. Throughout the study, participants undergo regular assessments including evaluations of disability, muscle strength, grip strength, and disease activity scores. Researchers monitor for relapses, adverse events, and changes in laboratory and clinical parameters. The primary outcome measures include the time to first relapse during Stage B, with additional secondary outcomes assessing clinical improvements, safety, and immunologic responses. Total participation may last several years depending on extension phase involvement.
1-10 of 15
1